Table 3.

Evidence of the effects of Nrf2 inducers in rodent models of chemotherapy-induced peripheral neuropathy (CIPN).

Nrf2 Inducer	Animals (Sex, Strain)	Dose (mg/kg), Route of Administration	Mechanism of Action	Reference
PEA-OXA	Male Wistar rats	10 mg/kg, oral	NF-κB/Nrf-2 pathway	[97]
Oleuropein	Male Wistar rats	Oleuropein—20 mg/kg, oral Combination—Oleuropein—20 mg/kg, oral + suvorexant—an orexin receptor antagonist—20 mg/kg, oral	Nrf2 pathway	[104]
Curcumin	Male Sprague Dawley rats	100 and 200 mg/kg, oral	Nrf2/HO-1 pathway	[98]
Mitoquinone	Male ICR mice	2.5, 5 and 10 mg/kg, intragastric	Nrf2 pathway	[96]
Formononetin	Male C57BL/6 mice	10 mg/kg, i.p. 10 µM on mouse ND7/23 neuron cells, colon cancer cells (CT-26), human colorectal carcinoma cells (Caco-2, DLD-1, and HCT-116), human lung adenocarcinoma cells (PC9, A649, H1975, and HCC8827), human lung squamous cell carcinoma cells (H520), and human pancreatic cancer cells (BxPC3 and Panc1)—in vitro	Keap1-Nrf2-GSTP1 pathway	[101]
Resveratrol	Male Sprague Dawley rats	7 and 14 mg/kg, oral	Nrf2/HO-1 pathway	[100]
Quercetin	Male Sprague Dawley rats	25 and 50 mg/kg, oral	Nrf2/HO-1 pathway	[99]
Oltipraz	Male Sprague Dawley rats	10, 50, 100 mg/kg/day, i.p.	Nrf2/HO-1 pathway	[91]
Rosiglitazone	Male Sprague Dawley rats	5, 25, and 50 mg/kg, i.p.	Nrf2/HO-1 pathway	[92]
Levo-corydalmine	Male ICR mice	5, 10, and 20 mg/kg, intragastric	Nrf2/HO-1/CO pathway	[94]
Berberine	Male Wistar rats	10 and 20 mg/kg, i.p.	Nrf2 pathway	[102]
Alphalipoic acid	Male Sprague Dawley rats	15, 30, and 60 mg/kg, i.p.	Nrf2 pathway	[95]
L-carnosine	Male and female Egyptian patients	500 mg, oral in patients—clinical trial	Nrf2 pathway	[107]
Dimethyl fumarate and its metabolite monomethyl fumarate	Rat	0.3, 1, 3, or 10 mM dimethyl fumarate or monomethyl fumarate on PC12 cell—a rat pheochromocytoma cell	Nrf2 pathway	[103]
Sulforaphane	Nrf2+/+ and Nrf2−/− C57BL/6 mice	5 mg/kg, i.p. 10 µM on DRG neurons	Nrf2 pathway	[89]

Note. Table is organized based on the most recent to oldest publications.